Moderna number of employees

Moderna reported 4,700 employees at December 31, 2025 in its latest annual report, down 1,100 (19.0%) on the year before. That compares with 2,700 at December 31, 2021. Revenue per employee was $413,617.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	4,700	−1,100 (19.0%)	$413,617	10-K, filed February 20, 2026
December 31, 2024	5,800	+200 (3.6%)	$557,931	10-K, filed February 21, 2025
December 31, 2023	5,600	+1,700 (43.6%)	$1.2m	10-K, filed February 23, 2024
December 31, 2022	3,900	+1,200 (44.4%)	$4.9m	10-K, filed February 24, 2023
December 31, 2021	2,700	—	$6.8m	10-K, filed February 25, 2022

What the annual reports say

HUMAN CAPITAL We had approximately 4,700 full-time employees in 18 countries as of December 31, 2025 . 2025 annual report
HUMAN CAPITAL We had approximately 5,800 full-time employees in 18 countries as of December 31, 2024 . 2024 annual report
HUMAN CAPITAL We had approximately 5,600 full-time employees in 19 countries around the world as of December 31, 2023. 2023 annual report
HUMAN CAPITAL We had approximately 3,900 full-time employees as of December 31, 2022, representing a substantial increase from 2,700 full-time employees as of the end of the prior year. 2022 annual report
HUMAN CAPITAL We had approximately 2,700 full-time employees as of December 31, 2021, representing a more than doubling of our workforce from 1,300 full-time employees as of the end of the prior year. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: EXEL vs MRNA ALKS vs MRNA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Moderna's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Moderna.